MAP Group Expands with SKC Acquisition

Deal News | Nov 25, 2024 | Osborne Clarke

MAP Group, a consultancy specializing in pharmaceuticals and biotech, has acquired SKC Beratungsgesellschaft mbH, a German strategy consultancy focused on market access and pricing. This acquisition seeks to extend MAP Group's offerings and geographical presence in Europe. Osborne Clarke advised on the deal, with a team led by Lorenz Chwaszcza and Dr. Nanni Spitzer. The SKC founding team will join MAP Group's leadership, further bolstering the firm's capabilities in facilitating patient access to healthcare solutions across Europe.

Sectors

Consulting
Pharmaceuticals and Biotechnology
Private Equity

Geography

United Kingdom – MAP Group is headquartered in the UK, and Osborne Clarke UK supported the transaction.
Germany – SKC Beratungsgesellschaft mbH, the acquired company, is based in Hanover, Germany.

Industry

Consulting – The article discusses the acquisition of a strategy consultancy firm (SKC) by another consultancy (MAP Group), emphasizing expansion in consulting services.
Pharmaceuticals and Biotechnology – MAP Group focuses on consulting in pharmaceuticals and biotech, helping clients navigate regulations in these sectors.
Private Equity – MAP Group is a portfolio company of Kester Capital, highlighting the role of private equity in funding and supporting acquisitions.

Financials

Participants

Name	Role	Type	Description
MAP Group	Buyer	Company	An international strategy consultancy focused on the pharmaceutical and biotech industries.
SKC Beratungsgesellschaft mbH	Target Company	Company	A German strategy consultancy specializing in market access for medicines and healthcare applications.
Osborne Clarke	Legal Advisor	Company	A law firm advising MAP Group on the acquisition.
Kester Capital	Private Equity Firm	Company	The private equity firm supporting MAP Group.
Steve Glass	CEO of MAP Group	Person	CEO of MAP Group who commented on the acquisition.